CAPTRUST Financial Advisors’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.66M Buy
42,403
+972
+2% +$67.7K ﹤0.01% 1066
2025
Q4
$2.75M Buy
41,431
+13,913
+51% +$899K 0.01% 932
2025
Q3
$1.85M Sell
27,518
-5,717
-17% -$452K ﹤0.01% 1067
2025
Q2
$2.9M Buy
33,235
+3,661
+12% +$287K 0.01% 811
2025
Q1
$2.02M Buy
29,574
+1,422
+5% +$116K 0.01% 901
2024
Q4
$2.19M Buy
28,152
+5,101
+22% +$378K 0.01% 850
2024
Q3
$1.55M Buy
23,051
+1,022
+5% +$83.9K ﹤0.01% 967
2024
Q2
$2.5M Sell
22,029
-247
-1% -$31.2K 0.01% 725
2024
Q1
$3.09M Sell
22,276
-22,084
-50% -$2.78M 0.01% 643
2023
Q4
$5.5M Buy
44,360
+6,781
+18% +$693K 0.02% 528
2023
Q3
$3.51M Buy
37,579
+10,664
+40% +$1.2M 0.01% 643
2023
Q2
$3.46M Buy
26,915
+7,166
+36% +$867K 0.01% 626
2023
Q1
$2.29M Sell
19,749
-356
-2% -$39.9K 0.01% 695
2022
Q4
$2.28M Buy
20,105
+1,091
+6% +$120K 0.01% 670
2022
Q3
$1.53M Buy
19,014
+4,205
+28% +$356K 0.01% 761
2022
Q2
$1.1M Sell
14,809
-1,963
-12% -$179K 0.01% 788
2022
Q1
$2.15M Buy
16,772
+4,008
+31% +$438K 0.01% 581
2021
Q4
$1.71M Buy
12,764
+528
+4% +$75.9K 0.01% 610
2021
Q3
$1.67M Sell
12,236
-3,280
-21% -$414K 0.01% 569
2021
Q2
$1.66M Sell
15,516
-1,444
-9% -$139K 0.02% 551
2021
Q1
$1.52M Buy
16,960
+8,868
+110% +$832K 0.02% 541
2020
Q4
$748K Buy
8,092
+892
+12% +$79.6K 0.01% 696
2020
Q3
$745K Buy
7,200
+868
+14% +$90.7K 0.01% 597
2020
Q2
$634K Buy
6,332
+796
+14% +$71.2K 0.01% 635
2020
Q1
$353K Sell
5,536
-204
-4% -$12.7K 0.01% 672
2019
Q4
$315K Buy
5,740
+5,456
+1,921% +$259K 0.01% 824
2019
Q3
$11K Hold
284
﹤0.01% 1460
2019
Q2
$11K Buy
284
+184
+184% +$5.78K ﹤0.01% 1467
2019
Q1
$3K Hold
100
﹤0.01% 1620
2018
Q4
$3K Hold
100
﹤0.01% 1424
2018
Q3
$4K Hold
100
﹤0.01% 1389
2018
Q2
$2K Hold
100
﹤0.01% 1404
2018
Q1
$2K Hold
100
﹤0.01% 1236
2017
Q4
$1K Buy
+100
New +$1.3K ﹤0.01% 1210

Other funds holding DXCM

CAPTRUST Financial Advisors's DXCM Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its DexCom (DXCM) stake by 2.3% in Q1 2026, buying an estimated $67.7K and bringing the position to 42,403 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1066.

CAPTRUST Financial Advisors first reported a position in DXCM in Q4 2017 and has held it in 34 quarters since. The position peaked at $5.5M in Q4 2023. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • CAPTRUST Financial Advisors held 42,403 shares of DexCom worth $2.66M as of Q1 2026.
  • CAPTRUST Financial Advisors bought 972 DexCom shares in Q1 2026, an estimated $67.7K.
  • DexCom made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1066 holding.
  • CAPTRUST Financial Advisors first reported a position in DexCom in Q4 2017 and has held it in 34 quarters since.
  • CAPTRUST Financial Advisors's DexCom position peaked at $5.5M in Q4 2023.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.